Toxins, Biological

Name
Toxins, Biological
Accession Number
DBCAT000185
Description

Specific, characterizable, poisonous chemicals, often PROTEINS, with specific biological properties, including immunogenicity, produced by microbes, higher plants (PLANTS, TOXIC), or ANIMALS.

Drugs
DrugDrug Description
Denileukin diftitoxA recombinant cytotoxic protein based on a combination of diphtheria toxin fragments and interleukin-2 used to treat cutaneous T-cell lymphoma by targeting the interleukin-2 receptor.
Botulinum toxin type BA purified form of botulinum toxin type B used to block acetylcholine release in the treatment of cervical dystonia and sialorrhea.
Botulinum toxin type AA purified form of botulinum toxin type A used to block acetylcholine release in the treatment of chronic sialorrhea, muscle spasticity, and dystonia, as well as in cosmetic applications.
ExenatideA GLP-1 agonist used in the management of type 2 diabetes mellitus.
BufotenineA hallucinogenic serotonin analog found in frog or toad skins, mushrooms, higher plants, and mammals, especially in the brains, plasma, and urine of schizophrenics. Bufotenin has been used as a...
EritoranInvestigated for use/treatment in sepsis and septicemia.
AncrodAn anticoagulant purified from the venom of the Malayan pit viper that functions by inactivating circulating plasma fibrinogen. Not currently approved for use or marketed in any country.
TopsalysinInvestigated for use/treatment in benign prostatic hyperplasia, cancer/tumors (unspecified), prostate cancer, prostate disorders, and solid tumors.
TetrodotoxinFor the treatment of chronic and breakthrough pain in advanced cancer patients as well as for the treatment of opioid dependence.
Cintredekin besudotoxInvestigated for use/treatment in brain cancer.
PraconaseInvestigated for use/treatment in spinal cord injuries.
ZiconotideAn N-type calcium channel antagonist used to manage patients with severe chronic pain who cannot tolerate, or who have not responded adequately to other treatments such as intrathecal morphine and systemic analgesics.
E5531Investigated for use/treatment in sepsis and septicemia.
SerotoninFor temporary relief of nervousness, anxiety, mood swings, joint pains, weakness, drowsiness, itching and lethargy. Not evaluated by the FDA, homeopathic product.
BatroxobinNo approved indications. Batroxobin is a defibrongenating agent which has been observed to reduce fibrinogen levels and thus reduce clot risk when used intravenously.
Bordetella pertussis pertactin antigenBordetella pertussis pertactin antigen is a vaccine for the prophylaxis of whooping cough that contains pertactin, a membrane-associated antigen of Bordetella pertussis .
ZeranolZeranol is a non-steroidal estrogen agonist. It is a mycotoxin, derived from fungi in the Fusarium family, and may be found as a contaminant in fungus-infected crops. It is 3-4x...
Recombinant Cholera Toxin B SubunitRecombinant Cholera Toxin B Subunit is an ingredient in the EMA-authorised product Dukoral.
BombesinBombesin is under investigation in clinical trial NCT01205321 (PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and...
CenderitideCenderitide is under investigation for the treatment of ST Elevation (STEMI) Myocardial Infarction of Anterior Wall.
CilengitideCilengitide has been used in trials studying the treatment of Sarcoma, Gliomas, Lymphoma, Leukemia, and Lung Cancer, among others.
MuscimolMuscimol has been used in trials studying the treatment of Epilepsy and Parkinson's Disease.
Naptumomab estafenatoxNaptumomab Estafenatox has been used in trials studying the treatment of Pancreatic Cancer, Renal Cell Carcinoma, and Non-Small-Cell Lung Carcinoma.
NeosaxitoxinNeosaxitoxin is under investigation in clinical trial NCT01786655 (Safety Study of Long-Acting Local Anesthetic).
alpha-Conotoxin VC 1.1Investigated for use/treatment in pain (acute or chronic).
AnfibatideAnfibatide is under investigation in clinical trial NCT01585259 (Anfibatide Phase Ib-IIa Clinical Trial).
ChlorotoxinChlorotoxin is under investigation in clinical trial NCT00733798 (A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma).
TozuleristideTozuleristide is under investigation in clinical trial NCT02464332 (Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery).
Chlorotoxin I-131Investigated for use/treatment in various forms of brain cancer; Malignant Glioma, Glioblastoma Multiforme, GBM, Anaplastic Astrocytoma, Oligo-Astrocytoma, Gliosarcoma
PatulinNot Annotated
HypothemycinNot Available
Drugs & Drug Targets
DrugTargetType
Denileukin diftitoxInterleukin-2 receptor subunit alphatarget
Denileukin diftitoxCytokine receptor common subunit gammatarget
Denileukin diftitoxInterleukin-2 receptor subunit betatarget
Botulinum toxin type BVesicle-associated membrane protein 1target
Botulinum toxin type BVesicle-associated membrane protein 2target
Botulinum toxin type BSynaptotagmin-2target
Botulinum toxin type ASynaptosomal-associated protein 25target
Botulinum toxin type ARho-related GTP-binding protein RhoBtarget
Botulinum toxin type ASerum albumincarrier
ExenatideGlucagon-like peptide 1 receptortarget
ExenatideSerum albumincarrier
ExenatideDipeptidyl peptidase 4enzyme
BufotenineAmine oxidase [flavin-containing] Aenzyme
EritoranToll-like receptor 4target
AncrodFibrinogen alpha chaintarget
TetrodotoxinSodium channel protein type 1 subunit alphatarget
TetrodotoxinSodium channel protein type 2 subunit alphatarget
TetrodotoxinSodium channel protein type 3 subunit alphatarget
TetrodotoxinSodium channel protein type 8 subunit alphatarget
Cintredekin besudotoxInterleukin-13target
ZiconotideVoltage-dependent N-type calcium channel subunit alpha-1Btarget
ZiconotideVoltage-dependent P/Q-type calcium channel subunit alpha-1Atarget
E5531Toll-like receptor 4target
SerotoninSolute carrier family 22 member 2transporter
SerotoninSodium-dependent serotonin transportertarget
Serotonin5-hydroxytryptamine receptor 2Atarget
Serotonin5-hydroxytryptamine receptor 3Atarget
Serotonin5-hydroxytryptamine receptor 3Btarget
SerotoninSynaptic vesicular amine transportertarget
ZeranolEstrogen receptor alphatarget
ZeranolSex hormone-binding globulintarget
MuscimolGamma-aminobutyric acid receptor subunit alpha-1target
MuscimolGamma-aminobutyric acid receptor subunit beta-3target
MuscimolGamma-aminobutyric acid receptor subunit gamma-2target
HypothemycinMitogen-activated protein kinase 1target